Three-Year Real-World Study Compares Burosumab Treatment with Oral Phosphate and Active Vitamin D in Adults with XLH
Financial Post ·
Publication in the Journal of Bone and Mineral Research offers new insight into the long-term XLH treatment experience PRINCETON, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) — Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced the publication of three-year real-world findings from an interim analysis of the […]
PRINCETON, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced the publication of three-year real-world findings from an interim analysis of the XLH Disease Monitoring Program (DMP) in the Journal of Bone and Mineral Research . The analysis assessed serum phosphate levels and patient-reported pain, stiffness, and physical function at years 1 and 3 among adults with X-linked hypophosphatemia (XLH) treated with burosumab or oral phosphate and active vitamin D (Pi/D). Read the full study here . Read More